Ikena Oncology Inc. (IKNA) NASDAQ
$1.26 0.02 (1.61%)
Market Cap: $59.84M
As of 04/18/24 04:00 PM EDT. Market closed.
Ikena Oncology Inc. (IKNA)
NASDAQ
$1.26
0.02 (1.61%)
Market Cap: $59.84M
As of 04/18/24 04:00 PM EDT. Market closed.
ikena oncology (formerly kyn therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. we are advancing multiple development and discovery programs: an ep4 receptor antagonist; an ahr antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting ... read more
ikena oncology (formerly kyn therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. we are advancing multiple development and discovery programs: an ep4 receptor antagonist; an ahr antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting the hippo signaling pathway; and a discovery-stage program against an undisclosed target.. in addition to raising capital from top tier investors orbimed advisors and atlas venture, we have entered into a global strategic collaboration with celgene on the ahr antagonist and kynase programs. “at ikena, we begin with the end in mind. we focus on subgroups of patients based on their biomarker profiles who will most benefit from our immunotherapy and tumor cell-targeted drug candidates, ensuring that we can bring the right drug to the right patient battling cancer.” mark manfredi, chief executi read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
ORBIMED ADVISORS LLC | Director | Jun 24, 2022 | Buy | $4.96 | 162,000 | 803,975 | 2,098,097 | Jun 24, 2022, 05:39 PM |
ORBIMED ADVISORS LLC | Director | Jun 23, 2022 | Buy | $3.71 | 23,419 | 86,884 | 1,936,097 | Jun 24, 2022, 05:39 PM |
ORBIMED ADVISORS LLC | Director | Jun 22, 2022 | Buy | $3.55 | 66,806 | 237,161 | 1,912,678 | Jun 24, 2022, 05:39 PM |
Bonita David P | Director | Jun 22, 2022 | Buy | $3.55 | 66,806 | 237,161 | 1,912,678 | Jun 24, 2022, 05:32 PM |
Bonita David P | Director | Jun 24, 2022 | Buy | $4.96 | 162,000 | 803,975 | 2,098,097 | Jun 24, 2022, 05:32 PM |
Bonita David P | Director | Jun 23, 2022 | Buy | $3.71 | 23,419 | 86,884 | 1,936,097 | Jun 24, 2022, 05:32 PM |
Tessier Maude | Chief Business Officer | Jan 18, 2022 | Option Exercise | $3.54 | 71,786 | 253,800 | 100,578 | Jan 20, 2022, 04:30 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Jan 10, 2022 | Option Exercise | $2.15 | 36 | 77 | 44,511 | Jan 12, 2022, 07:25 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Jan 11, 2022 | Option Exercise | $2.15 | 964 | 2,069 | 45,439 | Jan 12, 2022, 07:25 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Jan 10, 2022 | Sale | $12.00 | 36 | 432 | 44,475 | Jan 12, 2022, 07:25 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Jan 11, 2022 | Sale | $12.00 | 964 | 11,568 | 44,475 | Jan 12, 2022, 07:25 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Dec 10, 2021 | Option Exercise | $2.15 | 1,000 | 2,146 | 45,475 | Dec 14, 2021, 08:48 PM |
Zhang Xiaoyan Michelle | Chief Scientific Officer | Dec 10, 2021 | Sale | $14.76 | 1,000 | 14,760 | 44,475 | Dec 14, 2021, 08:48 PM |
FORMELA JEAN FRANCOIS | Director | Mar 30, 2021 | Buy | $16.00 | 125,000 | 2,000,000 | 874,634 | Dec 14, 2021, 08:29 PM |
FORMELA JEAN FRANCOIS | Director | Dec 10, 2021 | Sale | $15.03 | 11,989 | 180,195 | 1,256,224 | Dec 14, 2021, 08:29 PM |
FORMELA JEAN FRANCOIS | Director | Dec 14, 2021 | Sale | $14.00 | 5,959 | 83,426 | 1,241,935 | Dec 14, 2021, 08:29 PM |
FORMELA JEAN FRANCOIS | Director | Dec 13, 2021 | Sale | $14.64 | 8,330 | 121,951 | 1,247,894 | Dec 14, 2021, 08:29 PM |
Atlas Venture Fund XI, L.P. | 10% Owner | Mar 30, 2021 | Buy | $16.00 | 125,000 | 2,000,000 | 874,634 | Dec 14, 2021, 08:27 PM |
Atlas Venture Fund XI, L.P. | 10% Owner | Dec 14, 2021 | Sale | $14.00 | 5,959 | 83,426 | 1,241,935 | Dec 14, 2021, 08:27 PM |
Atlas Venture Fund XI, L.P. | 10% Owner | Dec 13, 2021 | Sale | $14.64 | 8,330 | 121,951 | 1,247,894 | Dec 14, 2021, 08:27 PM |
Atlas Venture Fund XI, L.P. | 10% Owner | Dec 10, 2021 | Sale | $15.03 | 11,989 | 180,195 | 1,256,224 | Dec 14, 2021, 08:27 PM |
Bonita David P | Director | Mar 30, 2021 | Buy | $16.00 | 423,400 | 6,774,400 | 1,845,872 | Apr 14, 2021, 06:29 PM |
ORBIMED ADVISORS LLC | Director | Mar 30, 2021 | Buy | $16.00 | 423,400 | 6,774,400 | 1,845,872 | Apr 13, 2021, 06:36 PM |
Stampacchia Otello | Director | Mar 30, 2021 | Option Exercise | $16.00 | 450,000 | 7,200,000 | 2,249,123 | Apr 01, 2021, 06:16 PM |
Bonita David P | Director | Mar 30, 2021 | Buy | $16.00 | 423,400 | 6,774,400 | 2,191,425 | Apr 01, 2021, 06:14 PM |
ORBIMED ADVISORS LLC | Director | Mar 30, 2021 | Buy | $16.00 | 423,400 | 6,774,400 | 2,191,425 | Apr 01, 2021, 06:13 PM |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ORBIMED ADVISORS LLC | 12,048,773 | 0.73% | No change | Other |
ORBIMED ADVISORS LLC | 3,539,358 | 0.14% | 11.09% | Other |
BLACKROCK INC. | 1,858,156 | 0.00009% | 28.49% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 529,369 | 0.00011% | 2.35% | Other |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 287,900 | 0.00117% | -29.42% | Other |
Period of Report: 12/31/2023
10-K/10-Q Filings: View